The impact of a second arterial graft on 5-year outcomes after coronary artery bypass grafting in the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery Trial and Registry.

PubWeight™: 1.38‹?› | Rank: Top 10%

🔗 View Article (PMID 26055439)

Published in J Thorac Cardiovasc Surg on May 08, 2015


Catalina A Parasca1, Stuart J Head1, Friedrich W Mohr2, Michael J Mack3, Marie-Claude Morice4, David R Holmes5, Ted E Feldman6, Antonio Colombo7, Keith D Dawkins8, Patrick W Serruys9, Arie Pieter Kappetein10, SYNTAX Investigators

Author Affiliations

1: Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands.
2: Department of Cardiac Surgery, Herzzentrum Universität Leipzig, Leipzig, Germany.
3: The Heart Hospital, Baylor Health Care Systems, Plano, Tex.
4: Department of Cardiology, Institut Cardiovasculaire Paris Sud, Massy, France.
5: Department of Cardiovascular Disease, Mayo Clinic, Rochester, Minn.
6: Department of Cardiology, North Shore University Health System, Evanston, Ill.
7: Department of Cardiology, San Raffaele Scientific Institute, Milan, Italy.
8: Boston Scientific Corporation, Natick, Mass.
9: Department of Cardiology, Erasmus University Medical Center, Rotterdam, The Netherlands.
10: Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands. Electronic address:

Associated clinical trials:

SYNTAX Study: TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries (SYNTAX) | NCT00114972

Articles citing this

Multiple arterial grafting: Stay the course. J Thorac Cardiovasc Surg (2015) 0.75

Articles by these authors

Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med (2009) 17.17

Do differences in repeat revascularization explain the antianginal benefits of bypass surgery versus percutaneous coronary intervention?: implications for future treatment comparisons. Circ Cardiovasc Qual Outcomes (2012) 1.50

Differences in baseline characteristics, practice patterns and clinical outcomes in contemporary coronary artery bypass grafting in the United States and Europe: insights from the SYNTAX randomized trial and registry. Eur J Cardiothorac Surg (2014) 1.39

Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J Cardiothorac Surg (2013) 1.24

Impact of 3-dimensional bifurcation angle on 5-year outcome of patients after percutaneous coronary intervention for left main coronary artery disease: a substudy of the SYNTAX trial (synergy between percutaneous coronary intervention with taxus and cardiac surgery). JACC Cardiovasc Interv (2013) 1.10

Risk profile and 3-year outcomes from the SYNTAX percutaneous coronary intervention and coronary artery bypass grafting nested registries. JACC Cardiovasc Interv (2012) 0.81

Impact of pre- and post-procedural anemia on the incidence of acute kidney injury and 1-year mortality in patients undergoing transcatheter aortic valve implantation (from the French Aortic National CoreValve and Edwards 2 [FRANCE 2] Registry). Catheter Cardiovasc Interv (2015) 0.77

Incidence, Characteristics, Predictors, and Outcomes of Repeat Revascularization After Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting: The SYNTAX Trial at 5 Years. JACC Cardiovasc Interv (2016) 0.77

Surgical or transcatheter mitral valve intervention: complex disease requires complex decisions. EuroIntervention (2014) 0.75

Characteristics of surgical prosthetic heart valves and problems around labeling: A document from the European Association for Cardio-Thoracic Surgery (EACTS)-The Society of Thoracic Surgeons (STS)-American Association for Thoracic Surgery (AATS) Valve Labelling Task Force. J Thorac Cardiovasc Surg (2019) 0.75

Cost-effectiveness of percutaneous coronary intervention versus bypass surgery from a Dutch perspective. Heart (2015) 0.75